Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma：A Systematic Evaluation.
10.7534/j.issn.1009-2137.2019.06.029
- Author:
Tao LUO
1
;
Hai-Long XIA
2
Author Information
1. Department of Hematology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
2. Department of Hematology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China,E-mail：xhl1999cn@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Humans;
Multiple Myeloma;
drug therapy;
Oligopeptides;
therapeutic use;
Remission Induction
- From:
Journal of Experimental Hematology
2019;27(6):1887-1893
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of carfilzomib in the treatment of multiple myeloma (MM).
METHODS:Computer was used to search PubMed, EMbase, Cochrane library and MEDLINE databases for carfilzomib treatment of MM. Clinical features and results were extracted and meta-analysis was performed using Stata12.0 software.
RESULTS:Twelve eligible Phase I/II, II and III clinical trials of carfilzomib were extracted and 2 487 MM patients involved in evaluable. The summary analysis showed that the rate of complete response (CR) of carfilzomib treatment was 28%, the rate of ≥very good partial response (VGPR) was 73%, and the rate of overall response rate (0RR) was 93%; the 1-year progression-free survival (PFS) rate of MM patients was 93%, the 2-year PFS rate was 85%, and the 3-year PFS rate was 74%. Three randomized controlled trials showed a significant improvement in ORR [OR=1.644, 95% CI=(1.056, 2.560) ] (P＜0.05) and clinical benefit rate (CBR) in MM patients [OR=1.595, 95%) CI=(1.044, 2.435) ] (P＜0.05). Compared with the control group, the OR of cardiotoxicity (P＜0.05) was significantly increased, while that of peripheral neuropathy (P＞0.05) was not significantly changed.
CONCLUSION:Compared with traditional treatments, carfilzomib significantly improves survival in the patients with multiple myeloma without increasing the incidence of peripheral neuropathy, but the incidence of cardiotoxicity seems higher.
